Sonya Tang Girdwood, MD, PhD
- Member, Division of Hospital Medicine
- Member, Division of Translational and Clinical Pharmacology
- Associate Professor, UC Department of Pediatrics
- sonya.tanggirdwood@cchmc.org
- Board Certified
About
Biography
I chose to specialize in hospital medicine because it allows me to collaborate with other subspecialties in the care of pediatric patients. I enjoy the acute-care aspect of hospital medicine and have the opportunity to develop relationships with the families of children with medically complex illnesses admitted to our inpatient unit.
Early on, I realized information regarding appropriate drug dosing in medically complex or critically ill children was lacking. So, my research explores how to personalize the dosing of antibiotics and other medications in critically ill patients and patients with complex diseases.
I focus on the pharmacokinetics and pharmacodynamics of antibiotics, specifically beta-lactams, in critically ill children. Additionally, I strive to better understand the timely transition of intravenous to enteral antibiotics in hospitalized children. Today, my clinical work informs my research so that any newly discovered information can impact my patient’s care.
As a clinical fellow, I received several notable awards, including:
- Cincinnati Children’s Hospital Medical Center Arnold Strauss Fellow Award
- Cincinnati Children’s Hospital Medicine Fellow Award
- Gerber Foundation Research Novice Award
As a faculty member, in addition to serving on the American Society of Clinical Pharmacology and Therapeutics Career Development Committee, I am also a member of their Scientific Programming Committee for the national conference. Locally, I am a co-director of the Genetic Pharmacology Service and the T32 Pediatric Clinical Pharmacology Fellowship.
During my first two years on faculty, I was supported by the National Institute of Child Health and Human Development (NICHD) K12 Child Health Research Career Development Award to study the impact of piperacillin/tazobactam pharmacokinetics on kidney injury. I’m currently funded by a National Institute of General Medicine Sciences (NIGMS) R35 Maximizing Investigators' Research Award to continue building the evidence of precision dosing of antibiotics in critically ill children.
BS: Massachusetts Institute of Technology, Cambridge, MA, 2004
MD: Johns Hopkins University, Baltimore, MD, 2013
PhD: Johns Hopkins University, Baltimore, MD, 2013
Residency: Cincinnati Children's, Cincinnati, OH, 2016
Chief Residency: Cincinnati Children's, Cincinnati, OH, 2017
Fellowship: Pediatric Hospital Medicine & T32 NICHD Clinical Pharmacology, Cincinnati Children's, Cincinnati, OH, 2020
Interests
Hospital medicine; complex care inpatient team
Services and Specialties
Interests
Pediatric clinical pharmacology; sepsis; model-informed precision dosing; IV to enteral antibiotic transition
Research Areas
Additional Languages
MandarinPublications
Population pharmacokinetics and Monte Carlo simulation of Cefepime in paediatric and Young adult bone marrow transplant patients. British Journal of Clinical Pharmacology. 2026.
Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood advances. 2026; 10(4):1106-1113.
Urine NGAL Adds to Serum Creatinine in Predicting Cefepime Clearance in Critically Ill Children at High Risk of Acute Kidney Injury. International Journal of Antimicrobial Agents. 2026; 107741.
Can a population pharmacokinetics model built on intermittent infusions accurately predict meropenem concentrations in children receiving continuous infusions? British Journal of Clinical Pharmacology. 2026; 92(2):619-624.
Advancing Pharmacoequity through Science, Innovation, and Partnership. Clinical Pharmacology and Therapeutics. 2026; 119(2):304-305.
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing. Journal of Antimicrobial Chemotherapy. 2026; 81(1).
From PICU to NICU: Extrapolating Meropenem Exposure From Pediatric to Neonatal Intensive Care Patients. Journal of Clinical Pharmacology. 2026; 66(1):e70097.
The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity. Clinical Pharmacology and Therapeutics. 2025.
The case for combined pediatric nephrology and clinical pharmacology training. Pediatric Nephrology. 2025.
Antimicrobial pharmacokinetics in pediatric patients on kidney replacement therapy: a comprehensive narrative review. Pediatric Nephrology. 2025.
From the Blog
Improved Piperacillin Dosing May Lower Risk of AKI in Critically Ill Patients
Sonya Tang Girdwood, MD, PhD, Stuart L. Goldstein, MD, FAAP, FNKF2/1/2023
Growing Need for Pharmacogenetics Data for Pediatric Medications
Sonya Tang Girdwood, MD, PhD3/9/2022
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey